Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Saeed Sadeghi
Olga Olevsky
Sara A Hurvitz

Division of Hematology & Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

Purpose: This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing studies evaluating this novel agent.

Background: The development of HER2-targeted therapies has dramatically improved clinical outcomes for patients with any stage of HER2-positive breast cancer. Although the positive effect of these treatments cannot be overstated, treatment resistance develops in the vast majority of those diagnosed with stage IV HER2-positive breast cancer. Moreover, HER2-directed therapies are most effective when combined with cytotoxic chemotherapy. The need for chemotherapy leads to significant adverse effects and a clear decrease in quality of life for those dealing with a chronic incurable disease. T-DM1 is a recently developed, novel antibody–drug conjugate in which highly potent maytansinoid chemotherapy is stably linked to the HER2-targeted monoclonal antibody, trastuzumab.

Results: Preclinical and phase 1–3 clinical data support the significant antitumor activity of T-DM1. Importantly, several randomized studies also now demonstrate its clear superiority in terms of tolerability compared with standard chemotherapy-containing regimens. Its role in the treatment of trastuzumab-resistant metastatic breast cancer has now been established on the basis of the results of two phase 3 randomized studies, EMILIA (An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer) and TH3RESA (A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy). The most common toxicities seen with T-DM1 are thrombocytopenia and an elevation in liver transaminases. Significant cardiac toxicity has not been demonstrated. Both in vitro cell line–based studies as well as exploratory analyses of archived tumor samples from the clinical trials are seeking to understand potential mechanisms of resistance to T-DM1. Ongoing studies are also evaluating the use of T-DM1 in the first-line metastatic, neoadjuvant, and adjuvant settings, as well as in combination with other targeted therapies.

Conclusion: T-DM1 represents the first successfully developed antibody drug conjugate for the treatment of HER2-positive advanced breast cancer.

Keywords: HER2, T-DM1, trastuzumab emtansine, ado-trastuzumab emtansine, metastatic breast cancer, Kadcyla

Introduction
Nearly three decades have passed since Slamon and colleagues demonstrated that amplification of the gene for human epidermal human growth factor receptor 2 (HER2) is associated with a more aggressive disease course and worse clinical
outcomes in patients with breast cancer.\(^1\) Trastuzumab (Herceptin; Genentech, South San Francisco, CA, USA), the first monoclonal antibody developed to target HER2, was shown to significantly improve the time to progression and overall survival (OS) of patients with metastatic HER2+ breast cancer.\(^2\) Significant disease-free survival and OS benefits were subsequently demonstrated in patients with localized HER2-positive (HER2+) disease with the addition of trastuzumab to standard adjuvant chemotherapy.\(^3-5\) In fact, trastuzumab has literally altered the natural history of HER2 overexpressing disease in both the metastatic and early disease settings, such that the survival for patients with trastuzumab-treated HER2+ breast cancer now mirrors, and may exceed, that of HER2-negative breast cancer.\(^6,7\) Despite the substantial activity of trastuzumab, resistance to therapy arises in the majority of patients with advanced disease. Lapatinib (Tykerb; GlaxoSmithKline, Brentford, United Kingdom), an orally bioavailable reversible inhibitor of the HER1 and HER2 tyrosine kinase domains, was subsequently shown to improve the time to progression for patients with HER2+ trastuzumab-pretreated metastatic breast cancer (MBC),\(^8\) leading to the US Food and Drug Administration (FDA) approving lapatinib plus capecitabine in this disease setting. Although this therapy provides patients with trastuzumab-resistant disease an additional treatment option, only 29% of patients had clinical benefit (complete response, partial response, or stable disease lasting at least 6 months), and half of patients had disease progression at 6.2 months.\(^9\) A variety of resistance mechanisms has been proposed including activation of alternative signaling pathways, receptor masking, truncated HER2, or expression of the ligands of other members of the epidermal growth factor receptor family.\(^10\) Therefore, there is a continued need to develop novel agents to target HER2-amplified disease. In 2013, the FDA approved the first successful HER2-targeted antibody–drug conjugate (ADC), trastuzumab emtansine (T-DM1; Kadcyla; Genentech), for the treatment of HER2+ trastuzumab-pretreated advanced breast cancer. This article reviews the mechanism of action of T-DM1, as well as existing clinical data, ongoing studies, and potential pathways of resistance to this novel agent.

**Mechanism of action of T-DM1**

T-DM1 is a novel ADC composed of trastuzumab connected via a stable thioether linker to a highly potent antimicrotubule derivative of maytansine 1 (DM1; N-methyl-N-[3-mercapto-1-oxopropyl]-l-alanine ester of maytansinol). DM1 is an inhibitor of microtubule dimerization, similar to vinka alkaloids, chosen as the cytotoxic component of T-DM1, given its high potency. In vitro studies have shown that in cancer cell lines, DM1 is 25–270 times more potent than paclitaxel.\(^11\) On average, 3.5 moieties of DM1 are linked via a nonreducible thioether bond (4-[N-maleimidomethyl] cyclohexane-1-carboxylate) to each trastuzumab antibody.\(^12\) T-DM1 is not the first ADC developed clinically; however, it is unique in that it is the first to use the 4-(N-maleimidomethyl) cyclohexane-1-carboxylate linker. Prior ADCs were designed using disulfide bond linkers, but experimental work showed that the oxidizing potential of lysosomes limited the cleavage of the disulfide bond within the cell.\(^13\) The 4-(N-maleimidomethyl) cyclohexane-1-carboxylate linker is advantageous, as it undergoes proteolytic digestion once internalized, and furthermore, given its greater stability, it is safer, as it limits the release of DM1 into the circulation.\(^14\) On binding the extracellular domain of HER2, T-DM1 enters the cell by the process of receptor-mediated endocytosis, and DM1 dissociates from the linker by proteolysis, presumably in the lysosome.\(^15\) In the cell cytoplasm, DM1 disrupts microtubule dynamics leading to cell cycle arrest and induction of apoptosis.\(^14\) In addition to being a cytotoxic agent, T-DM1 maintains the activity of trastuzumab by inhibiting HER2-directed signal transduction as well as activating antibody-dependent cell-mediated cytotoxicity (Figure 1).\(^11\) Preclinical work by Lewis Phillips and colleagues in a mouse xenograft model demonstrated that although T-DM1 had minimal cytotoxic effects in breast cancer cell lines lacking HER2 overexpression, it was capable of eliciting cell death in HER2 overexpressing cell lines, including those resistant to trastuzumab.\(^12\) Pharmacokinetic evaluation across multiple studies shows that the half-life of T-DM1 is approximately 4 days, and the clearance of the drug is predominantly via the biliary and gastrointestinal systems.\(^16\)

The HER2-targeted nature of T-DM1 should theoretically limit the delivery of the cytotoxic component to HER2+ cells. Despite this, thrombocytopenia has been observed in all clinical trials of T-DM1 to date. Mahapatra and colleagues studied the effects of T-DM1 on platelet formation from hematopoietic stem cells as well as platelet function in vitro and demonstrated that T-DM1 is internalized in a HER2-independent fashion into megakaryocytes and that the intracellular release of DM1 leads to a reduction in the stem cell population.\(^17\) More recently, Thon and coworkers evaluated the rate and extent of megakaryocyte differentiation and proplatelet production in vitro, using a novel high-content, live cell imaging assay. Their work confirmed that T-DM1 is endocytosed into megakaryocytes and that DM1 disrupts the
Targeting HER2 breast cancer with T-DM1

microtubule cytoskeleton and inhibits proplatelet production while also inhibiting megakaryocyte differentiation.\textsuperscript{18}

**Completed clinical studies**

**Phase 1 trials**

T-DM1 was first evaluated in a phase 1, open-label, multicenter, dose-escalation study (TDM3569g) in which patients with HER2+ MBC whose disease had progressed on prior trastuzumab-containing therapy were assigned to one of two dosing regimens: every 21 days or weekly.\textsuperscript{19,20}

The three (q3) weekly dosing cohort was enrolled first. A total of 24 patients received escalating doses of intravenous T-DM1 starting at 0.3 mg/kg every 21 days.\textsuperscript{19} The median number of prior regimens received in the metastatic setting was four (range, one to eight), and 58% of patients had at least three distinct sites of metastatic disease. Dose-limiting grade 4 thrombocytopenia was observed in two of three patients treated with 4.8 mg/kg, and the maximum tolerated dose (MTD) was identified as 3.6 mg/kg. In this heavily pretreated patient population, six of 24 patients achieved a partial response, five of which were confirmed, yielding an overall objective response rate (ORR) of 21%. A total of 15 patients were treated with 3.6 mg/kg. The clinical benefit rate (objective response plus stable disease at 6 months) among the 15 patients who were treated at the MTD was 73%. Of these 15 patients, nine had measurable disease, including four patients who had a confirmed partial response for an ORR of 44% (four of nine) in this group. The most commonly reported all-grade adverse events (AEs) were thrombocytopenia (54.2%), elevated transaminases (41.7%), fatigue (37.5%), anemia (29.2%), and nausea (25%). Of note, no neuropathy was noted in the study.\textsuperscript{19}

In the second part of this study, 28 patients with HER2+ MBC were treated with escalating doses of weekly T-DM1, starting at 1.2 mg/kg.\textsuperscript{20} Two of three patients treated with 2.9 mg/kg developed grade 3 AEs (one grade 3 aspartate ami-
notransferase elevation and one grade 3 thrombocytopenia), thus establishing the MTD of the weekly regimen as 2.4 mg/kg. Objective partial responses were seen in 13 of the 28 patients (46.4%). A total of 16 patients were treated at the MTD, 15 of whom had measurable disease. The ORR in these 15 patients was 40% (six of 15). Similar to the q3 weekly dosing regimen, there was no grade 3 neuropathy observed, and the rate of grade 3/4 AEs (68%) was similar to that reported with the q3 weekly regimen (50%). It is interesting to consider that the weekly regimen delivers twice as much T-DM1 and, based on these data, appears to have similar tolerability to the q3 weekly regimen. Although the ORR of all patients enrolled is higher with the weekly regimen, given the very small size of this study, a relative comparison of efficacy is not possible. Ongoing studies are evaluating the weekly regimen further. A summary of Phase 1 trials are provided in Table 1.

**Phase 2 trials**

TDM4258 was a proof-of-concept phase 2 study to evaluate the activity and safety of q3 weekly T-DM1 in patients with previously treated HER2+ MBC. In this single-group, open-label study, 112 heavily pretreated patients were enrolled. The median number of previous lines of therapy was 8 and included prior taxane (84%), anthracycline (71%), capecitabine (66%), and carboplatin (42%). Prior lapatinib was used in 60% of patients. The ORR was 25.9%, and the median progression-free survival (PFS) was 5.3 months by independent review. Among patients previously treated with lapatinib (n=66), the ORR was 24.2%, and the median PFS was 4.2 months. The safety profile was similar to that reported in the phase 1 studies. Importantly, no patients developed grade 3/4 congestive heart failure or left ventricular ejection fraction decline, and no patients came off study because of cardiac toxicity. HER2 status was evaluated centrally on tumors from 95 patients and was found to be positive in 74. The ORR in those patients with confirmed HER2+ tumors was 33.8%, and median PFS was 8.2 months. Interestingly, 21 patients had HER2 normal tumors, and of those, only one patient had an objective response.

A confirmatory, single-group phase 2 study (TDM4374g) of q3 weekly T-DM1 was conducted in 110 patients who had been previously exposed to trastuzumab, anthracyclines, taxanes, and capecitabine. In contrast to the TDM4258 study, this study required patients to have received prior lapatinib. The primary endpoint was independently assessed ORR. The ORR was 34.5% (38/110), clinical benefit rate was 48.2%, and duration of response was 7.2 months. The median PFS was 6.9 months by independent review. The ORR was similar for patients who had documented progression on prior lapatinib, trastuzumab, and chemotherapy. Central confirmation of HER2+ status was performed on archival tumor tissue from 95 patients. Of these patients, 15 were found to be HER2 normal, three of whom had an objective response (20%). In contrast, 41% of patients with centrally confirmed HER2+ disease had an objective response. The most common all-grade AEs were fatigue, nausea, and thrombocytopenia, and the most frequent grade 3/4 AEs were thrombocytopenia, fatigue, and cellulitis. Elevation of aspartate aminotransferase occurred in 26%, and of ALT in 14%, of the patients. A total

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Patients, n</th>
<th>Treatment groups</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1</td>
<td>TDM3569g</td>
<td>Dose escalation, T-DM1 q3 weeks</td>
<td>ORR, 44%; CBR, 73%</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Cohort 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>TDM4258g</td>
<td>T-DM1: 3.6 mg/kg IV q3 weeks</td>
<td>PFS, 4.6 months; ORR, 26%</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>TDM4374g</td>
<td>T-DM1: 3.6 mg/kg IV q3 weeks</td>
<td>PFS, 7.3 months; ORR, 35%; CBR, 48%</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>TDM4450g</td>
<td>T-DM1: 3.6 mg/kg IV versus capecitabine + trastuzumab</td>
<td>PFS, 14.2 months; ORR, 64%</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>137</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>TDM4373g</td>
<td>T-DM1: 3.6 mg/kg IV + pertuzumab 840 mg loading</td>
<td>PFS, 6.6 months; ORR, 57%</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>64</td>
<td>dose followed by 420 mg IV q3 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Phase 3**

<table>
<thead>
<tr>
<th>Patients, n</th>
<th>Treatment groups</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 3</td>
<td>EMILIA</td>
<td>T-DM1: 3.6 mg/kg IV q3 weeks versus capcitabine + lapatinib</td>
</tr>
<tr>
<td>991</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TH3RESA**

<table>
<thead>
<tr>
<th>Patients, n</th>
<th>Treatment groups</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T-DM1: 3 mg/kg IV q3 weeks versus physician choice</td>
<td>PFS, 6.2 months; ORR, 31%</td>
</tr>
<tr>
<td>602</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** T-DM1, trastuzumab emtansine; q1 weekly; q3 every 3 weeks; ORR, objective response rate; CBR, clinical benefit rate defined as objective response plus stable disease lasting at least 6 months; IV, intravenous; PFS, progression-free survival; OS, overall survival; EMILIA: An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer; TH3RESA: A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician’s Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy; HER2, human growth factor receptor 2.
of nine patients (8%) experienced grade 3 or higher hepatic event, including seven patients with grade 3 laboratory abnormalities, one patient with grade 3 liver toxicity, and one patient who had a fatal hepatic event. Thrombocytopenia was also observed in 38% of patients. However, hemorrhagic events were typically mild, with the exception of one grade 3 epistaxis. Similar to the TDM4258 study, no patients came off study because of cardiac toxicity.23

The first randomized study to evaluate T-DM1 was a phase 2 trial (TDM4450g) comparing q3 weekly T-DM1 to q3 weekly docetaxel plus trastuzumab in 137 patients with previously untreated HER2+ MBC.24 Patients in the control group received trastuzumab (8 mg/kg intravenous loading dose, followed by 6 mg/kg thereafter) plus docetaxel (75 or 100 mg/m², per investigator choice). The ORR (58% in the control group versus 64% in the T-DM1 group; P=0.458) and clinical benefit rate were similar in the two treatment groups; however, T-DM1 was associated with a significant 5 month prolongation in median PFS (9.2 months versus 14.2 months; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36–0.97). The median duration of response was 9.5 months in the docetaxel/trastuzumab group and was not reached in the TDM-1 group. Importantly, there was a much lower rate of grade 3/4 AEs in the T-DM1 group (90.9% versus 46.4%), underscoring the considerable safety imparted by targeted delivery of chemotherapy using an ADC that has a stable linker. In fact, grade 4 AEs occurred in 58% of patients in the standard docetaxel/trastuzumab group compared with only 6% in the T-DM1 group. In the docetaxel/trastuzumab group, the most common toxicities were alopecia, neutropenia, diarrhea, and fatigue. More patients in the control group used colony-stimulating factors compared with in the T-DM1 group (44% versus 6%). In the TDM-1 group, the AEs consisted mostly of fatigue, nausea, elevated serum aspartate aminotransferase, fever, and headache.24 The lower rate of AEs in the T-DM1 group translated to an improvement in quality of life. The time to a decrease in 5 or more points in the Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) score was significantly delayed in the TDM-1 group (3.5 months in the control group versus 7.5 months in the TDM1 group; HR, 0.58; 95% CI, 0.36–0.92; P=0.022).24

The safety and activity of dual-HER2 (see Table 1) targeted therapy with T-DM1 plus another HER2-targeted monoclonal antibody, pertuzumab, was evaluated in a phase 2a trial, TDM4373g.25 In this study, 64 patients with HER2+ MBC (43 in the second-line or greater setting and 21 in the first-line setting) were treated with T-DM1 (3.6 mg/kg) plus pertuzumab (840 mg loading dose, followed by 420 mg) q3 weeks. Of the 21 first-line patients, 86% had received trastuzumab in the early-stage setting. The 43 patients who were previously treated for MBC had received a median of six prior lines of nonhormonal therapy. The ORR for the entire population was 41%. In the first-line patients, the ORR was 57% and in the advanced setting was 33%. The median PFS was 6.6 months, with 7.7 months in the first-line and 5.5 months in the second-line patients and beyond. The most common grade 3 or higher AEs were thrombocytopenia (13%), fatigue (11%), and transaminase elevations (9%).25

Phase 3 trials

In the landmark phase 3 EMILIA trial, 991 patients with metastatic or locally advanced trastuzumab-pretreated HER2+ disease were randomly assigned to receive either lapatinib (1,250 mg daily continuously) plus capecitabine (1,000 mg/m² by mouth twice a day, 14 days on, 7 days off) or T-DM1 q3 weeks.26 The primary endpoints were PFS, OS, and safety. The median PFS was 9.6 months in the T-DM1 group versus 6.4 months in the lapatinib plus capecitabine group (HR, 0.65; 95% CI, 0.55–0.77; P<0.001). At the second interim analysis, median OS crossed the stopping boundary for efficacy and was increased by 5 months in the TDM1 group (30.9 months versus 25.1 months; HR, 0.68; 95% CI, 0.55–0.85; P<0.001). Secondary endpoints including ORR (43.6% versus 30.8%; P<0.001) and median duration of response (12.6 months versus 6.5 months) favored T-DM1. In addition, the median time to decrease of 5 points or more in the Functional Assessment of Cancer Therapy-Breast (FACT-B TOI) score was delayed in the TDM1-treated patients (7.1 months versus 4.6 months; HR, 0.80; 95% CI, 0.67–0.95; P=0.012).

Grade 3/4 AEs were less frequent in the T-DM1-treated patients compared with the control group patients (40.8% versus 57.0%). The most common grade 3/4 AEs in the T-DM1-treated patients were thrombocytopenia and increased liver transaminases, and the most common grade 3/4 AEs in control group patients were diarrhea and palmar-plantar erythrodysesthesia. Of note, the rate of cardiac dysfunction was similar in both groups, with a total of 1.7% of patients in the TDM1 group and 1.6% of patients in lapatinib plus capecitabine group having an ejection fraction that was below 50%, or at least 15% below baseline. Grade 3 congestive heart failure was seen in only one patient in the T-DM1 group.26

The activity of T-DM1 in the lapatinib-pretreated HER2+ MBC setting was explored in the TH3RESA study.27 In this second phase 3 trial of T-DM1, patients who had received at least two HER2-targeted therapies for advanced disease, including both trastuzumab and lapatinib, were randomized...
in an open-label fashion to receive T-DM1 or treatment of physicians choice (TPC). A total of 602 patients were randomized in a 2:1 ratio to T-DM1 (3.6 mg/kg q21 days) or TPC. Stratification was based on region of the world, number of prior regimens, and presence or absence of visceral disease. Coprimary endpoints were investigator-assessed PFS and OS in the intent-to-treat population. Patients had received a median of four prior regimens for MBC. In the TPC group, 83% of the patients received HER2-targeted therapy as part of their regimen, and 17% received single-agent chemotherapy alone. The median PFS was significantly longer in the T-DM1 group compared with in the TPC group (6.2 months versus 3.3 months; HR, 0.528; 95% CI, 0.442–0.661; P<0.0001). There was a trend for improved survival with T-DM1, but the stopping boundary was not crossed at the first interim analysis. The ORR was also significantly improved in patients with measurable disease treated with T-DM1 (31% versus 9%, 95% CI, 16.2–29.2; P<0.0001). In terms of grade 3 or greater toxicities, thrombocytopenia was the only AE reported more commonly in the T-DM1 group. Overall, 18% of patients in the T-DM1 group and 21% of patients in the TPC group experienced a significant adverse event.27

The consistent PFS and ORR benefit seen in these two published phase 3 trials confirm that T-DM1 is a highly active and better-tolerated agent for patients with HER2+ MBC after the first-line setting (Table 1). Unfortunately, patients eventually experience disease progression on T-DM1; hence, discovering molecular markers that can predict response or resistance to this therapy remains a high priority.

**Predictors of response or resistance to T-DM1**

HER2 expression levels do appear to influence the efficacy outcomes associated with T-DM1. In exploratory analyses of several phase 2 and phase 4 studies, HER2 expression levels were measured on archived tumor samples by quantitative reverse transcription polymerase chain reaction. Patients were grouped according to whether their HER2 expression was greater than or less than the median. Of 50 patients included in the TDM4258g analysis, the median PFS was not reached (95% CI, 4.6 months–non estimable [NE]) for those with median HER2 expression or worse and was 4.2 months (95% CI, 2.7–6.8 months) for those patients with lower than median HER2 expression.22 In the TDM4374 trial, patients in whom HER2 expression was at least the median had a higher ORR of 42% and a PFS of 8.0 months compared with those in whom HER2 expression level was below the median (ORR, 38%; PFS, 6.2 months).23 Improved ORR and PFS were also reported in pertuzumab plus T-DM1-treated patients with tumor HER2 mRNA levels at the median or higher in the TDM4373g study.25 A similar analysis was undertaken in the TDM4450 study, in which HER2 mRNA levels were available for 116/137 patients: 61 in the control group and 55 in the T-DM1 group.28 In this randomized study, the relative risk of progressive disease in the overall population was reduced by 41% with T-DM1 compared with chemotherapy plus trastuzumab. This effect was even higher in patients with HER2 mRNA levels at least the median (61% relative risk reduction favoring the T-DM1 group; HR, 0.39; 95% CI, 0.18–0.85) compared with those with HER2 mRNA levels less than the median (15% relative risk reduction favoring the T-DM1 group; HR, 0.85; 95% CI, 0.44–1.67). The median PFS was not reached in the T-DM1 group in patients with HER2 mRNA at least median and was 10.6 months for those with HER2 mRNA less than median. In the control group (trastuzumab/docetaxel), median PFS was not significantly different (8.8 months versus 9.8 months with HER2 mRNA at the median or higher versus lower than median, respectively).28 Biomarker analysis of the EMILIA trial further confirmed this observation. Patients with tumors expressing HER2 levels greater than median had an OS of 34.1 months and a PFS of 10.6 months compared with 26.5 months and 8.2 months, respectively, for patients with HER2 levels less than or equal to the median.29 The consistent observation that HER2 expression influences response to T-DM1 is intriguing, but further analyses including prospective studies are needed to confirm the threshold of HER2 expression required for a response to this therapy.

**Drug efflux pumps**

P glycoprotein 1 (also known as MDR1) is the best-known transporter that mediates the efflux of toxins and drugs from the cell. MDR1 expression has been associated with poor response to chemotherapy in malignancies.30 In one study, a T-DM1-resistant cell line was shown to have upregulation of the MDR transporters.31 Another study evaluated two cell lines (JIMT1 and MDA-MB-361) that had conditioned resistance to a trastuzumab–maytansinoid conjugate (JIMT-TM and 361-TM) and showed that JIMT-TM resistance may be related to downregulation in HER2 expression, as well as increased expression in proteins related to posttranslational modification and endosomal proteins; however, drug efflux proteins were not altered. In contrast, in 361-TM cells, an increase in ABCB1 (MRP1) was seen without any changes in ABCB1 (MDR1).32 Additional studies are needed to assess the importance of MDR in mitigating clinical resistance to T-DM1.
PIK3CA mutations

At least one mechanism involved in the oncogenic function of HER2 is activation of the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway. Activating mutations in the catalytic subunit of the PI3K (PIK3CA) can result in increased activity of this pathway. It is estimated that 20%–40% of HER2+ breast cancers have activating mutations in PIK3CA. Preclinical work has demonstrated that HER2+/PIK3CA mutant tumors are resistant to trastuzumab alone or in combination with lapatinib or pertuzumab. Exploratory analyses from two recent trials confirm this laboratory phenomenon. The NeoSphere study was a randomized phase 2 trial that demonstrated that dual HER2-targeting with neoadjuvant pertuzumab, trastuzumab, and docetaxel was associated with a higher pathological complete response (pCR) rate of 45.8% compared with three other combinations (docetaxel and trastuzumab [pCR, 29%], trastuzumab and pertuzumab [pCR, 16.8%], and docetaxel and pertuzumab [pCR, 24.0%]). The rate of pCR was lower in all four groups in patients whose tumors bore PIK3CA mutations (24%) compared with patients without PIK3CA mutations (35%). Biomarker analysis of the NeoALTTO trial, another neoadjuvant study in HER2+ breast cancer that evaluated lapatinib and/or trastuzumab plus paclitaxel, also confirms this observation. Patients whose tumors had PIK3CA mutations had a lower pCR rate, with the most notable difference in the group containing both lapatinib and the trastuzumab group (55.8% without mutations versus 28.6% with mutations). Interestingly, an exploratory analysis on the EMILIA trial confirms that PIK3CA mutations were associated with a decrease in PFS in the capcitabine/lapatinib group (6.4 months wild-type versus 4.3 months mutated); however, the presence of PIK3CA mutations did not correlate with outcome in the T-DM1 group (9.8 months wild-type versus 10.9 months mutated). Thus, although the presence of PIK3CA mutations may be prognostic for poorer outcome in patients treated with trastuzumab, pertuzumab, or lapatinib, this marker does not appear to be prognostic of outcome in patients treated with T-DM1.

Neuregulin-HER3 signaling

Recent translational work provides some evidence that resistance to T-DM1 may in part be mediated by neuregulin and HER3 signaling. Neuregulin-1 is a ligand that binds to HER3, inducing a conformational change allowing HER3 to dimerize with HER2. HER2:HER3 dimers are highly potent activators of the PI3K pathway. Pertuzumab, a monoclonal HER2-targeted antibody, binds to and blocks HER2 at the HER3-binding domain, thus abrogating PI3K signaling. Preclinical work led by Phillips and colleagues demonstrated that in the presence of neuregulin, enhanced antiproliferative effects were seen when T-DM1 was combined with pertuzumab compared with T-DM1 alone in three cell lines (Calu-3 lung, BT-474, and SK-BR-3). There was no combination effect seen in KPL-4 cells that harbor PIK3CA-activating mutations, however, even in the presence of neuregulin. These intriguing preclinical results led to the phase 1b/2 TDM4373g clinical trial evaluating pertuzumab plus T-DM1 in HER2+ MBC (see “Phase 2 trials” section).

Future directions

Although the benefit of T-DM1 in patients with pretreated, locally advanced, or metastatic HER2+ breast cancer is clear, additional studies are needed to evaluate the benefit of T-DM1 in combination with other agents as well as its role in early-stage HER2+ disease. One ongoing trial, MARIANNE (A Study of Trastuzumab Emtansine [T-DM1] Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer, NCT01120184), is a three-group study in previously untreated locally advanced or metastatic HER2+ breast cancer that compares trastuzumab plus taxane, T-DM1 plus pertuzumab, and T-DM1 plus placebo. All patients are treated until disease progression with primary endpoint of PFS and a secondary endpoint of OS, as well as biomarker studies. This study has completed accrual with results anticipated in late 2014. The TDM4652g trial (NCT00951665) is a phase 1b trial exploring the combination of T-DM1, paclitaxel ± pertuzumab in previously treated patients with metastatic breast cancer. Finally, the BP22572 trial (NCT00934856) is a phase 1b/2a trial to explore combination of T-DM1 with docetaxel with or without pertuzumab in previously treated HER2+ MBC.

The activity and safety of T-DM1 in early breast cancer is being explored by several other trials. The ATEMPT (T-DM1 vs Paclitaxel/Trastuzumab for Breast, NCT01853748) trial is a phase 2 study in which patients with stage 1 HER2+ breast cancer are randomized to T-DM1 every 3 weeks for 17 weeks or to a combination of trastuzumab and paclitaxel weekly for 12 weeks followed by maintenance trastuzumab to complete 1 year. The primary endpoint of the trial is disease-free survival, and the secondary endpoint is OS. The randomized, open-label phase 3 KAITLIN (A Study of Kadcyla [Trastuzumab Emtansine] Plus Perjeta [Pertuzumab] Following Anthracyclines in Comparison With Herceptin [Trastuzumab] Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer, NCT01966471) trial is comparing the combination of trastuzumab and pertuzumab plus docetaxel versus T-DM1 and pertuzumab in patients with HER2+ breast cancer.
a taxane versus T-DM1 plus pertuzumab after completion of adjuvant anthracycline-containing chemotherapy. The role of T-DM1 in the neoadjuvant setting is being explored in the KRISTINE (A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer, NCT02131064) trial. In this open-label phase 2 trial, patients are randomized to either six cycles of q3 weekly docetaxel, carboplatin, trastuzumab, and pertuzumab or T-DM1 and pertuzumab before definitive surgery. Another neoadjuvant study is ADAPT (A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine [T-DM1] With or Without Standard Endocrine Therapy vs Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in

### Table 2 Ongoing clinical trials with T-DM1

<table>
<thead>
<tr>
<th>Trial name</th>
<th>Phase</th>
<th>Patient population</th>
<th>Number to be enrolled</th>
<th>Treatment groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARIANNE (NCT01120184)</td>
<td>3</td>
<td>First-line HER2+ MBC</td>
<td>1,092</td>
<td>T-DM1 + placebo versus T-DM1 + pertuzumab versus trastuzumab + a taxane</td>
</tr>
<tr>
<td>TDM46562 (NCT00951665)</td>
<td>Ib</td>
<td>Previously treated HER2+ MBC</td>
<td>107</td>
<td>T-DM1 + paclitaxel ± pertuzumab</td>
</tr>
<tr>
<td>BP22572 (NCT00934856)</td>
<td>Ib/2a</td>
<td>Previously treated HER2+ MBC</td>
<td>99</td>
<td>T-DM1 + docetaxel ± pertuzumab</td>
</tr>
<tr>
<td>KAITLIN (NCT01966471)</td>
<td>3</td>
<td>Adjuvant</td>
<td>2,500</td>
<td>AC/FEC → T-DM1/pertuzumab versus AC/FEC → trastuzumab/pertuzumab/taxane</td>
</tr>
<tr>
<td>ATEMPT (NCT01853748)</td>
<td>2</td>
<td>Stage I adjuvant</td>
<td>500</td>
<td>T-DM1 ×1 year versus paclitaxel/trastuzumab × 12 weeks, followed by trastuzumab maintenance to complete 1 year</td>
</tr>
<tr>
<td>KRISTINE (NCT02131064)</td>
<td>2</td>
<td>Neoadjuvant</td>
<td>432</td>
<td>T-DM1/pertuzumab versus taxotere/carboplatin/trastuzumab/pertuzumab</td>
</tr>
<tr>
<td>ADAPT (NCT01745965)</td>
<td>2</td>
<td>Neoadjuvant</td>
<td>380</td>
<td>T-DM1 ± endocrine therapy versus trastuzumab + endocrine therapy for 12 weeks before surgery</td>
</tr>
<tr>
<td>KATHERINE (NCT01772472)</td>
<td>3</td>
<td>Residual disease after neoadjuvant therapy</td>
<td>1,484</td>
<td>T-DM1 versus trastuzumab maintenance for 14 cycles after surgery</td>
</tr>
<tr>
<td>Trastuzumab and Pertuzumab followed by T-DM1 in MBC (NCT01835236)</td>
<td>2</td>
<td>First-line HER2+ MBC</td>
<td>208</td>
<td>Trastuzumab and pertuzumab (no chemotherapy) in first-line MBC followed by T-DM1 in second-line MBC in the event of progression versus trastuzumab/pertuzumab/paclitaxel or vinorelbine in first-line MBC followed by T-DM1 in second-line MBC in event of progression</td>
</tr>
<tr>
<td>BYL719 + T-DM1 in HER2(+) Metastatic Breast CancerPts Who Progress on Prior Trastuzumab and Taxane Tx (NCT02038010)</td>
<td>1</td>
<td>Previously treated HER2+ MBC with progression on prior trastuzumab and taxane-based therapy</td>
<td>28</td>
<td>Oral GDC-0941 (PI3K inhibitor) daily and T-DM1 or trastuzumab</td>
</tr>
<tr>
<td>GDC-0941 administered orally to patients with Trastuzumab-DM1 or trastuzumab (NCT00928330)</td>
<td>1</td>
<td>Previously treated HER2+ MBC who progressed on trastuzumab-based therapy</td>
<td>57</td>
<td>T-DM1 intravenously every 3 weeks in combination with lapatinib daily plus abraxane intravenously weekly</td>
</tr>
<tr>
<td>STELA (NCT02073916)</td>
<td>1</td>
<td>Previously treated MBC with at least two prior therapies</td>
<td>18</td>
<td>ONT380 orally twice a day with T-DM1 intravenously</td>
</tr>
<tr>
<td>ONT380 + TDM1 (NCT01983501)</td>
<td>1</td>
<td>Previously treated HER2+ MBC with taxane and trastuzumab</td>
<td>48</td>
<td>T-DM1 intravenously on day 1 with PD-0332991 (palbociclib) on days 5–18 of every 21-day cycle</td>
</tr>
<tr>
<td>Phase Ib Study of PD-0332991 in Combination With T-DM1 (NCT01976169)</td>
<td>1</td>
<td>Previously treated MBC with HER2+ and RB proficient tumor</td>
<td>17</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** MARIANNE, A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer; HER, human growth factor receptor; MBC, metastatic breast cancer; TDM46562g, A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer; T-DM1, trastuzumab emtansine; BP22572, A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer; KAITLIN, A Study of Kadcyla (Trastuzumab Emtansine Plus Perjeta) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer; AC/FEC, adriamycin, cyclophosphamide/5-fluorouracil, epirubicin, and cyclophosphamide; ATEMPT, T-DM1 vs Paclitaxel/Trastuzumab for Breast; KRISTINE, A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer; ADAPT, A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol; KATHERINE, A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy; GDC-0941 administered orally to patients with Trastuzumab-DM1 or trastuzumab, Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy; STELA, TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer; ONT380 + TDM1, A Phase Ib Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer.
Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol, (NCT01745965), a randomized trial evaluating T-DM1 (with or without endocrine therapy) versus trastuzumab plus endocrine therapy for 12 weeks before definitive surgery in HER2+/hormone receptor–positive breast cancer. The KATHERINE (A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy, NCT01772472) trial will enroll patients who had residual disease at the time of definitive surgery after standard neoadjuvant trastuzumab-based therapy to either T-DM1 or trastuzumab maintenance for 14 cycles after surgery.

In addition to the abovementioned trials, studies are ongoing that will evaluate the combination of T-DM1 with other biologically targeted therapies. The BYL719 + T-DM1 trial (BYL719 + T-DM1 in HER2+ Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab and Taxane Tx, NCT02038010) is a phase 1 trial exploring the safety of combination of BYL719, a PI3K inhibitor with T-DM1 in patients whose metastatic disease has progressed on prior trastuzumab and taxane-based therapy. Another PI3K inhibitor, GDC-0941 is also being evaluated in a phase 1 study (GDC-0941 + TDM1 or Trastuzumab, Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy, NCT00928330) in combination with trastuzumab or T-DM1 for patients whose disease progressed on previous trastuzumab-based therapy. The STELA (TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer, NCT02073916) trial is an open-label study to assess the tolerability and safety of combination of T-DM1 to lapatinib and nab-paclitaxel in patients with HER2+ breast cancer who have received at least two prior therapies for their malignant disease. Dual HER2 blockade with the novel small molecule inhibitor of HER2, ONT-380 (A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine [T-DM1] in Patients With HER2+ Breast Cancer), along with T-DM1 is being evaluated in a small phase 1 study (NCT01983501) that will enroll 48 patients. Finally, the potential benefit of CDK4/6 inhibition in combination with T-DM1 will be evaluated in a phase 1 study of PD-0332991 along with T-DM1 (NCT01976169). In this study patients, will receive T-DM1 on day 1 followed by PD-0332991 orally on days 5–18 of every 21-day cycle. The ongoing clinical trials have been summarized in Table 2. Collectively, these trials will help not only address the role T-DM1 may have in early breast cancer but also elucidate the benefit of T-DM1 in combination with chemotherapy as well as other targeted therapies such as pertuzumab.

Conclusion
T-DM1 is the first example of a successfully developed ADC for the treatment of breast cancer. The collective published studies in phase 1 and 2, as well as the results of two large randomized phase 3 trials, EMILIA and TH3RESA, have demonstrated that T-DM1 is an efficacious and safe therapeutic intervention for HER2+ metastatic breast cancer. In spite of its success, disease progression on T-DM1 does occur; therefore, greater understanding of pathways of resistance is crucial in improving the efficacy. Ongoing studies will evaluate combining T-DM1 with other targeted therapies and using T-DM1 in the early setting.

Disclosure
SAH has received contracted funding from Genentech/Roche (paid to the University of California, Los Angeles) for research and education and has had travel reimbursed for speaking at international conferences. SS has received honoraria from Genentech/Roche for speaker programs. OO reports no conflicts of interest in this work.

References


